BofA sees termination of Owens–Rotech deal as surprising but potentially positive

Owens & Minor and Rotech Healthcare mutually terminated their planned acquisition due to antitrust concerns raised by the FTC, resulting in OMI incurring $100 million in termination costs, including an $80 million payment to Rotech, and a subsequent plan to redeem $1 billion in notes. Bank of America views the termination as potentially beneficial for Owens & Minor, allowing them to refocus on core operations and potential asset sales, despite initially expecting the deal to add 15 cents to EPS by year two; BofA reiterated its "Underperform" rating on OMI but raised its price objective to $7.50.

Analysis

Owens & Minor's (NYSE:OMI) mutual termination of its planned Rotech Healthcare acquisition, prompted by U.S. Federal Trade Commission antitrust concerns, represents an unforeseen shift in strategy. This decision will cost OMI approximately $100 million, including an $80 million payment to Rotech, and involves redeeming $1 billion in notes and cancelling related loan commitments. Bank of America analysts, while finding the termination surprising, view it as potentially beneficial, allowing OMI to refocus on its core operations, cost management, and potential asset divestitures, such as its Products and Healthcare Services (HCSG) unit, thereby avoiding a complex integration. The Rotech acquisition was projected to add 15 cents to earnings per share by the second year; however, Rotech's recent performance has been subdued, with a reported 4% year-over-year revenue decline in 2024. Despite the termination costs, Bank of America reiterated an "Underperform" rating on OMI but increased its price objective to $7.50 from $7.00, citing greater strategic clarity and a prospective reduction in OMI's debt burden. Owens & Minor is now anticipated to explore smaller acquisitions within its Patient Direct business.

Key Decisions for Investors

• Investors should monitor Owens & Minor's ability to execute its refocused strategy on core operations and cost control, especially considering the $100 million termination cost and the foregone earnings accretion from the Rotech deal.
• Consider the impact of the termination expenses and the $1 billion note redemption on OMI's near-term financial position, weighed against the potential long-term advantages of a streamlined business and reduced leverage.
• Observe developments concerning the potential sale of the Products and Healthcare Services (HCSG) unit and any new, smaller acquisitions in the Patient Direct segment, as these will be critical indicators of the revised strategic direction.
• Acknowledge Bank of America's sustained "Underperform" rating, which, despite a slightly increased price target to $7.50, signals ongoing caution regarding OMI's outlook until tangible benefits from this strategic realignment are evident.